Reference : Comment je previens ... les maladies cardio-vasculaires par une approche pharmacologi...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Cardiovascular & respiratory systems
Comment je previens ... les maladies cardio-vasculaires par une approche pharmacologique combinee: y a-t-il place pour une polypill"?"
[en] Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a polypill"?"
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Lefebvre, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Kulbertus, Henri mailto [Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Antihypertensive Agents/administration & dosage ; Aspirin/administration & dosage ; Cardiovascular Diseases/prevention & control ; Drug Combinations ; Folic Acid/administration & dosage ; Hematinics/administration & dosage ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/administration & dosage
[en] In the June 28, 2003 issue of the British Medical Journal, an extensive literature survey based on various large meta-analyses of the efficacy and safety of the reduction of four cardiovascular risk factors (cholesterol, arterial blood pressure, platelet aggregation, homocysteine) leads to the conclusion that a combined pharmacological intervention should reduce ischaemic heart disease events by 88% and strokes by 80% in at risk individuals. Therefore, a new paradigm is proposed for the prevention of cardiovascular diseases. This new strategy would consist in the systematic prescription to people with a history of heart attack or stroke, those with any form of obliterative atherosclerotic vascular disease or diabetes, and everyone aged 55 and older of a fixed combination of 6 pharmacological agents independently of initial risk factor profile.... Such pharmacological formulation, called "polypill", should contain a statin, three blood pressure lowering drugs (each at half standard dose), aspirin (75 mg/day) and folic acid (0.8 mg/day). We discuss the pros and cons of this new paradigm. However, the efficacy of such "polypill" remains to be demonstrated in a large controlled clinical trial as well as its superiority as compared to a classical approach of cardiovascular prevention based upon the individual optimal correction of each risk factor thanks a dose titration of each pharmacological compound.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
200309_04.pdfNo commentaryPublisher postprint458.53 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.